Sellas Life Sciences: A Legal Probe, a Stubborn Event Count, and a Pipeline Waiting in the Wings

Sellas faces a Pomerantz securities probe over disclosure timing as its Phase 3 REGAL study stands at 78 of 80 events, with SLS009 data due Q4 2026.

Few corners of the market demand as much composure from investors as clinical oncology, where value is set not by quarterly nuance but by statistical thresholds and unforgiving trial protocols. Sellas Life Sciences sits squarely in that pressure cooker — and right now the heat is coming from two directions at once.

On one side stands the Phase 3 REGAL study of Galinpepimut-S (GPS), the company's lead candidate being tested as maintenance therapy in acute myeloid leukemia patients in second complete remission. On the other sits a securities investigation that has thrust the company's disclosure practices into the spotlight.

A Law Firm Moves In

Pomerantz LLP launched a probe into Sellas on September 10 over suspected securities fraud, and followed up with outreach to investors on Friday. The allegations center on the timing of disclosures — specifically, the claim that the study had already hit a predefined event target before that fact was made public.

The company, according to media reports, countered on Friday with a figure of 78 of the 80 events required for the final analysis. That gap between the two accounts is the crux of the dispute, and it lands during an already delicate stretch for the biotech. Such investigations are a familiar sight in the U.S. capital markets, but they tend to strike research-stage companies where it hurts most: investor confidence in how management communicates.

For all the noise, the clinical facts carry more weight than the legal maneuvering. Until the trial protocol is formally complete, the probe reads largely as background music to a highly volatile chapter.

Counting Down to 80

Because REGAL is event-driven, and because the company remains blinded to the clinical results, every additional day of waiting ratchets up market jitters. The tally stood at 78 of 80 predefined events as of the most recent count. That is the number that matters — not the courtroom chatter.

What's Being Overlooked

Meanwhile, progress elsewhere in the pipeline has been pushed to the margins. Roughly two weeks ago, three abstracts on SLS009 (tambiciclib) in models of ductal pancreatic cancer were accepted for the AACR special conference on pancreatic cancer, running September 25–28 in San Diego.

The work, conducted with the University of Wisconsin School of Medicine and Public Health, relies on patient-derived organoid models carrying mutated KRAS. The presentations cover MYC allele imbalance as well as synthetic lethality achieved by combined BET and CDK9 inhibition in MYC-amplified pancreatic cancer. The company will also present a dual, selective inhibition strategy targeting CDK9 and KRAS-G12D.

None of that, however, will settle the near-term fate of SLS009. That hinges on testing in humans: first overall results from the randomized study are expected in the fourth quarter of 2026.

A Balance Sheet That Buys Time

At least the finances provide breathing room. As of June 30, 2026, the close of the second quarter, Sellas held cash and cash equivalents of $138.3 million. That cushion drew a constructive response from analysts over the summer.

The Scoreboard

The stock closed yesterday down 4.3% at EUR 9.76. Even after that pullback, the shares are up 244% since the start of the year — a spread between short-term swings and operating substance that remains striking.

Sellas is standing at a pivotal marker. The stretch leading to the final data unblinding will not be comfortable, and the legal questions have yet to be resolved. But the path to a regular study readout still looks more probable than the current cloud of legal uncertainty — a reminder of just how merciless the tempo of late-stage drug development can be, and how little preclinical wins and early groundwork do to calm the market while the wait drags on.